IgA nephropathy shortly follwed by seroconversion of positive anti-GBM antibodies and rapid progressive glomerulonephritis in a Chinese boy: coincidental overlap or pathogenic link? Authors: Xu Zhang, Fengjie Yang, Shiyi Wu, Yu Zhang, Jianhua Zhou Published: 2026 ABSTRACT BackgroundAnti-glomerular basement membrane (anti-GBM) disease is a rare, aggressive autoimmune disorder that seldom coexists with IgA nephropathy (IgAN). The development of anti-GBM disease secondary to IgAN in pediatric patients—specifically with confirmed seroconversion—is exceptionally rare. We present a case of a 14-year-old boy who developed anti-GBM disease shortly after an initial diagnosis of IgAN.Case presentationA 14-year-old male presented with a 10-day history of gross hematuria. Initial evaluation showed normal renal function and negative anti-GBM antibodies. The initial renal biopsy confirmed IgAN (Lee grade V; Oxford classification M1E0S1T0-C2). Despite receiving continuous Nefecon monotherapy (16 mg/day) combined with irbesartan 150 mg/day, his renal function deteriorated rapidly four months later, with serum creatinine (Scr) surging from 65 to a peak of 665 µmol/L. Repeat serological testing revealed a significant seroconversion of anti-GBM antibodies from negative to strongly positive (> 8.0 AI). A second renal biopsy demonstrated devastating progression, with 100% fibrocellular crescent formation and intense linear IgG deposition along the glomerular capillary walls. The patient received an intensified regimen consisting of plasmapheresis, hemodialysis, and cyclophosphamide pulse therapy. Following treatment, his anti-GBM antibodies turned negative, and renal function stabilized without dialysis, though it did not return to the pre-morbid baseline.ConclusionsWe report a pediatric male case in whom anti-glomerular basement membrane disease developed secondarily during the clinical course of IgA nephropathy. This case strongly suggests that in patients with newly diagnosed chronic glomerulonephritis, such as IgA nephropathy, a high index of suspicion for concurrent autoimmune diseases including anti-glomerular basement membrane disease should be maintained when rapid progression of glomerulonephritis occurs. Introduction Anti-glomerular basement membrane (anti-GBM) nephritis is a rare and highly aggressive autoimmune disease, immunologically characterized by elevated levels of autoantibodies directed against the non-collagenous domain 1 of the α3 chain of type IV collagen (α3IVNC1). Pathologically, the disease is characterized by linear IgG deposition along the glomerular capillary walls, while clinically, it typically manifests as rapidly progressive glomerulonephritis (RPGN) accompanied by extensive crescent formation [1, 2]. Despite its exceedingly low annual incidence, anti-GBM nephritis progresses rapidly, often leading to a dismal prognosis if timely intervention is not initiated. Clinically, anti-GBM nephritis frequently co-occurs with other glomerular diseases [3]. The “double-positive” association with antineutrophil cytoplasmic antibodies (ANCA) is well-recognized [4–6], and cases overlapping with membranous nephropathy (MN) have also been reported [7, 8]. However, anti-GBM nephritis secondary to IgA nephropathy (IgAN) remains exceptionally rare worldwide. Herein, we report the case of a male pediatric patient diagnosed with anti-GBM disease during the clinical course of IgAN. At initial presentation, the patient tested negative for anti-GBM antibodies, and IgAN was confirmed via renal biopsy. Approximately four months later, his anti-GBM antibody titer became strongly positive, with a subsequent biopsy confirming the development of rapidly progressive glomerulonephritis. Case presentation A 14-year-old male pediatric patient presented to our hospital with a 10-day history of gross hematuria. Urinalysis showed urinary protein 2 + and urinary occult blood 3+, and urinary sediment showed erythrocyte levels of 2380.5/µl. Blood tests showed a serum creatinine (SCr) level of 78 µmol/L. LInitial serological screening, including anti-GBM antibodies, antineutrophil cytoplasmic antibodies, and antinuclear antibodies, all yielded negative results. Subsequently, the patient underwent his first renal biopsy, which revealed mesangial proliferative glomerulonephritis. Notably, cellular crescents are identified in approximately half of the glomeruli, and a single large fibrocellular crescent is occasionally observed. (Fig. 1). Immunofluorescence (IF) microscopy demonstrated prodominant (++++) IgA and moderate (++) IgG deposition localized within the mesangium, while no abnormalities were observed along the glomerular capillary walls (Fig. 1; Table 2). Electron-dense revealed that dumpy electron-dense deposits in mesangial areas, a few subendothelial deposits, and thickness of some segments of GBM (Fig. 2). Fig. 1Histopathology of the first renal biopsy (400x). A. Periodic acid-Schiff stained sections: Mesangial proliferative glomerulonephritis with a fibro-cellular crescent. B-D: Immunofluorescence shows granular mesangial deposits of IgA, IgG, and C3 Histopathology of the first renal biopsy (400x). A. Periodic acid-Schiff stained sections: Mesangial proliferative glomerulonephritis with a fibro-cellular crescent. B-D: Immunofluorescence shows granular mesangial deposits of IgA, IgG, and C3 Fig. 2Electron microscopy of initial renal biopsy showing mesangial changes and deposits. Electron microscopy of the initial renal biopsy reveals mesangial hypercellularity and matrix expansion, ranging from mild to focally moderate in severity. Additionally, electron-dense deposits are observed within the mesangium Electron microscopy of initial renal biopsy showing mesangial changes and deposits. Electron microscopy of the initial renal biopsy reveals mesangial hypercellularity and matrix expansion, ranging from mild to focally moderate in severity. Additionally, electron-dense deposits are observed within the mesangium After kidney biopsy, the patient was diagnosed as IgA nephropathy (Lee grade V; Oxford classification M1E0S1T0-C2), with normal renal function and moderate proteinuria. Treatment was initiated promptly with intravenous methylprednisolone pulse therapy administered to the patient at a maximum dose of 500 mg per day for 3 consecutive days. Due to persistent gross hematuria and many cresents formation (althought small), the patient was initially treated with intravenous methylprednisolone pulse therapy at a dosage of 500 mg per day for 3 consecutive days, irbesartan was given at 150 mg/day from admission. The patient showed some inprovement, gross hematuria and edema gradually disappereaded, thus discharged from our hospital and followed with administration of Nefecon (an oral targeted-release formulation of budesonide) at a dosage of 16 mg/day. This therapeutic strategy was selected considering the patient’s pediatric status and the high risk of long-term toxicities associated with conventional intensive immunosuppression. By specifically targeting the Peyer’s patches in the distal ileum (the primary site of mucosal galactose-deficient immunoglobulin A1 production), this approach aimed to address the upstream pathogenesis of IgAN. Furthermore, this regimen was intended to provide a ‘steroid-sparing’ effect to preserve the patient’s growth potential and, crucially, to avoid the gonadotoxicity and myelosuppression typically associated with the cyclophosphamide-based induction therapy traditionally utilized for crescentic IgAN. Within one week after diagnosis, the patient developed low-grade fever with a peak temperature of 37.5℃ that subsided after physical cooling, accompanied by worsened cough and yellow sputum, and was diagnosed with bronchopneumonia upon presentation to our hospital; urinalysis showed a UPCR of approximately 1500 ug/mg Cr and urinary red blood cells of 12,000/ul. The patient was treated with antibiotics for pneumonia, which was cured later and followed by significany decrease of urine protein-to-creatinine ratio of approximately 900 ug/mg Cr and urinary red blood cells of 2000/ul. Following two months of treatment, the patient’s SCr decreased and stabilized at approximately 65 µmol/L. Concurrent urinalysis revealed a reduction in urinary erythrocyte levels to 1792.1/µL, whereas no significant improvement was observed in proteinuria. Despite receiving continuous Nefecon monotherapy (16 mg/day) combined with irbesartan 150 mg/day since the initial diagnosis, the patient’s clinical course deteriorated significantly four months later after first biopsy. Without any prior dose tapering or discontinuation, the patient experienced a recurrence of gross hematuria, followed by a rapid decline in renal function. Specifically, the Scr doubled from 65 to 130 µmol/L within one month, reaching the level of AKI stage 2. Urinalysis revealed a red blood cell count of 4512.8 cells/µL and a urinary protein excretion of 1642.47 µg/mg Cr (Fig. 3). Laboratory findings upon readmission, which eventually led to the detection of anti-GBM antibodies, are summarized in Table 1. Table 1Laboratory data on admissionLaboratory testlaboratory valuesUnitReference Ranges Complete blood count RBC3.55 × 1012/L4.5–5.9WBC9.05 × 109/L4.1–11.0Hb102g/L129–172PLT291 × 109/L150.0-407.0 Clinical biochemistry TP62.6g/L66–87Alb36.5g/L40–55AST18U/L9–50ALT20U/L15–40LDH239U/L120–250BUN7.5mmol/L1.7–8.3Cr130µmol/L59–104Na139.5mmol/L136–145K4.7mmol/L3.5–5.1Cl105.7mmol/L99–110Ca2.33mmol/L2.1–2.55 Immune-related C31.47g/L0.65–1.39C40.21g/L0.16–0.38lgG5.9g/L7.0-15.6lgA2.24g/L0.58–3.21lgM1.13g/L0.49–2.61PR3-ANCA< 0.2< 1.0MPO-ANCA< 0.2< 1.0ANCA-NegativeANA-NegativeAnti-GBM antibody> 8.0AI< 1.0 Urinalysis Occult blood3+NegativeURBCs4512.8/µlNegativeUPCR1642.47µg/mgCr0-150UWBC120/µlNegativeβ2-MG0.53mg/L< 0.2WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; PLT, platelets; TP, total protein; Alb, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; Cr, creatinine; Na, sodium; K, potassium; Cl, chloride; Ca, calcium; C3, complement component 3; C4, complement component 4; IgG, immunoglobulin G; IgA, immunoglobulin A; IgM, immunoglobulin M; PR3-ANCA, proteinase 3 anti-neutrophil cytoplasmic antibody; MPO-ANCA, myeloperoxidase anti-neutrophil cytoplasmic antibody; UPCR, urine protein-to-creatinine ratio; β2-MG, beta-2 microglobulin Table 1Laboratory data on admissionLaboratory testlaboratory valuesUnitReference Ranges Complete blood count RBC3.55 × 1012/L4.5–5.9WBC9.05 × 109/L4.1–11.0Hb102g/L129–172PLT291 × 109/L150.0-407.0 Clinical biochemistry TP62.6g/L66–87Alb36.5g/L40–55AST18U/L9–50ALT20U/L15–40LDH239U/L120–250BUN7.5mmol/L1.7–8.3Cr130µmol/L59–104Na139.5mmol/L136–145K4.7mmol/L3.5–5.1Cl105.7mmol/L99–110Ca2.33mmol/L2.1–2.55 Immune-related C31.47g/L0.65–1.39C40.21g/L0.16–0.38lgG5.9g/L7.0-15.6lgA2.24g/L0.58–3.21lgM1.13g/L0.49–2.61PR3-ANCA< 0.2< 1.0MPO-ANCA< 0.2< 1.0ANCA-NegativeANA-NegativeAnti-GBM antibody> 8.0AI< 1.0 Urinalysis Occult blood3+NegativeURBCs4512.8/µlNegativeUPCR1642.47µg/mgCr0-150UWBC120/µlNegativeβ2-MG0.53mg/L< 0.2WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; PLT, platelets; TP, total protein; Alb, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; Cr, creatinine; Na, sodium; K, potassium; Cl, chloride; Ca, calcium; C3, complement component 3; C4, complement component 4; IgG, immunoglobulin G; IgA, immunoglobulin A; IgM, immunoglobulin M; PR3-ANCA, proteinase 3 anti-neutrophil cytoplasmic antibody; MPO-ANCA, myeloperoxidase anti-neutrophil cytoplasmic antibody; UPCR, urine protein-to-creatinine ratio; β2-MG, beta-2 microglobulin Laboratory data on admission WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; PLT, platelets; TP, total protein; Alb, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; Cr, creatinine; Na, sodium; K, potassium; Cl, chloride; Ca, calcium; C3, complement component 3; C4, complement component 4; IgG, immunoglobulin G; IgA, immunoglobulin A; IgM, immunoglobulin M; PR3-ANCA, proteinase 3 anti-neutrophil cytoplasmic antibody; MPO-ANCA, myeloperoxidase anti-neutrophil cytoplasmic antibody; UPCR, urine protein-to-creatinine ratio; β2-MG, beta-2 microglobulin Fig. 3Clinical course after admission. Cre: serum creatinine level, PEX: plasma exchange, mPSL: methylprednisolone, PSL: prednisolone, CTX: cyclophosphamide, HD: hemodialysis Clinical course after admission. Cre: serum creatinine level, PEX: plasma exchange, mPSL: methylprednisolone, PSL: prednisolone, CTX: cyclophosphamide, HD: hemodialysis To investigate the etiology of the RPGN, a repeated serological evaluation was performed. The results revealed that anti-GBM antibodies had seroconverted from negative to strongly positive (titer > 8.0 AI), while ANCA remained negative (Fig. 4). Upon the diagnosis of anti-GBM disease, the therapeutic regimen was promptly escalated. The patient first received intravenous methylprednisolone pulse therapy (500 mg/day for 3 consecutive days). Due to the progressive rise in serum creatinine (Scr), Cyclophosphamide Pulse Therapy was administered at a dose of 600 mg/day for 3 consecutive days (cumulative dose 1.8 g). Despite these measures, the Scr peaked at 511 µmol/L. Consequently, plasma exchange (PE) was initiated on day 7. A total of six PLEX sessions were performed with a tailored replacement volume of 1200 mL per session (approximately 0.5 times the estimated plasma volume). The replacement fluid was a composite of 500 mL fresh frozen plasma, 500 mL frozen plasma, and 200 mL 5% albumin; this conservative volume was specifically chosen to minimize pediatric-specific risks, such as circulatory overload and severe transfusion-related allergic reactions, while ensuring effective antibody clearance. Following these interventions, the anti-GBM antibody titer decreased significantly to 2.7 AI after the third PE session, and the Scr dropped to 269 µmol/L following the final session. To manage renal dysfunction during this period, the patient underwent four consecutive sessions of hemodialysis (HD), which stabilized the Scr at approximately 300µmol/L. Throughout the PE/HD phase and the subsequent follow-up, an additional 10 doses of low-dose CTX were administered to maintain immunosuppression. By day 40, the Scr remained stable at approximately 250 µmol/L. The patient was then transitioned to a maintenance regimen of oral prednisone (60 mg/day).” Fig. 4Clinical course before admission. Anti-GBM antibody: anti-glomerular basement membrane antibody, Cre: serum creatinine level, URBC: Urine Red Blood Cell Count, UPCR: Urine Protein-to-Creatinine Ratio Clinical course before admission. Anti-GBM antibody: anti-glomerular basement membrane antibody, Cre: serum creatinine level, URBC: Urine Red Blood Cell Count, UPCR: Urine Protein-to-Creatinine Ratio A second renal biopsy was performed four weeks post-admission, following a month of intensive treatment and clinical stabilization, to reassess the histological activity and the extent of chronicity. The results confirmed a devastating progression of the disease: all 15 sampled glomeruli exhibited epithelial-fibrous crescent formation (100%), the majority of which are large Cellular crescents involve half of the glomeruli, and segmental sclerosis is noted in a few glomeruli. Moderate tubular atrophy and interstitial expansion are present, accompanied by interstitial fibrosis and mononuclear inflammatory cell infiltration (Fig. 5). Shift from prodominant mesangial IgA deposits to strong linear deposition of IgG was identified via IF microscopy: strong linear deposition of IgG along cappilary loops and moderate deposition of IgA in mesangial deposits was observed, standing in stark contrast to the granular mesangial deposition noted during the first biopsy. Simultaneously, C3 (+++) deposition was observed within both the mesangium and along the glomerular capillary walls (Fig. 5). The clinical and histological features characterizing the transition from IgA nephropathy to anti-GBM disease (Cresent glomerulonephritis) are summarized in Table 2. Fig. 5Histopathology of the second renal biopsy (400x). A. Periodic acid-Schiff stained sections: Diffuse fibrocellular crescent formation, with segmental sclerosis observed in some glomeruli. B-D: Immunofluorescence shows linear staining for IgG and IgA along the glomerular capillary walls. C3 deposits are granular and localized to the mesangium, with segmental involvement of some capillary walls Histopathology of the second renal biopsy (400x). A. Periodic acid-Schiff stained sections: Diffuse fibrocellular crescent formation, with segmental sclerosis observed in some glomeruli. B-D: Immunofluorescence shows linear staining for IgG and IgA along the glomerular capillary walls. C3 deposits are granular and localized to the mesangium, with segmental involvement of some capillary walls Table 2Clinical and histological presentation at the time of first and second renal biopsyFirst biopsySecond biopsy Clinical presentation UPCR 299.14 ug/mgUPCR 3739.2 ug/mgURBCs 2380.5 /ulURBCs 3015.2 /ulScr 78umol/LScr 535 umol/L Anti-GBM antibody 0.4 AI> 8.0AI → 0.7 AI Light microscopy Total Glomeruli1815Crescent Formation9/18 (50%, Cellular)15/15 (100%, Fibro-cellular)Predominant LesionMesangial proliferationDiffuse crescentic GN Immunofluorescence IgG++ (Mesangial)++++ (Linear along GBM)IgA++++ (Mesangial)++ (Linear & Mesangial)C3-++ (Mesangial & GBM) C4 -- C1q -++ Fibrin +++++ Kappa ++++++ lambda ++++++UPCR, urine protein-to-creatinine ratio; URBCs: urine red blood cells; Scr: Serum creatinine; GBM: glomerular basement membrane; GN: glomerulonephritis; C3: complement component 3; C4:complement component 4;C1q: Complement component 1q; IgG: immunoglobulin G; IgA: mmunoglobulin A Table 2Clinical and histological presentation at the time of first and second renal biopsyFirst biopsySecond biopsy Clinical presentation UPCR 299.14 ug/mgUPCR 3739.2 ug/mgURBCs 2380.5 /ulURBCs 3015.2 /ulScr 78umol/LScr 535 umol/L Anti-GBM antibody 0.4 AI> 8.0AI → 0.7 AI Light microscopy Total Glomeruli1815Crescent Formation9/18 (50%, Cellular)15/15 (100%, Fibro-cellular)Predominant LesionMesangial proliferationDiffuse crescentic GN Immunofluorescence IgG++ (Mesangial)++++ (Linear along GBM)IgA++++ (Mesangial)++ (Linear & Mesangial)C3-++ (Mesangial & GBM) C4 -- C1q -++ Fibrin +++++ Kappa ++++++ lambda ++++++UPCR, urine protein-to-creatinine ratio; URBCs: urine red blood cells; Scr: Serum creatinine; GBM: glomerular basement membrane; GN: glomerulonephritis; C3: complement component 3; C4:complement component 4;C1q: Complement component 1q; IgG: immunoglobulin G; IgA: mmunoglobulin A Clinical and histological presentation at the time of first and second renal biopsy UPCR, urine protein-to-creatinine ratio; URBCs: urine red blood cells; Scr: Serum creatinine; GBM: glomerular basement membrane; GN: glomerulonephritis; C3: complement component 3; C4:complement component 4;C1q: Complement component 1q; IgG: immunoglobulin G; IgA: mmunoglobulin A Ultimately, a final diagnosis of IgAN complicated by anti-GBM nephritis was established. Following six sessions of plasmapheresis, four sessions of hemodialysis, and multiple rounds of immunosuppressive pulse therapy, the patient’s anti-GBM antibody titers gradually declined and eventually turned negative (Fig. 3). Although his renal function reached a plateau of stability, it failed to return to the pre-morbid baseline level. Discussion and conclusions We presented a pediatric case of anti-GBM disease happened during the acute course of IgA nephropathy. The patient moved to anti-GBM nephritis from IgAN, with a marked seroconversion of anti-GBM antibodies from negative to strongly positive. A unexpected shift from predominant mesangial IgA deposition to strong linear IgG deposition along GBM and marked expansion of glomerular crescents with less than 4 months. Although Matsuno and Kojima et al. [6, 9] have described similar associations, to our knowledge, such a rapid progression to anti-GBM nephritis following the diagnosis of IgAN has not been previously documented. IgAN is the most prevalent primary glomerulonephritis worldwide and is immunohistologically defined by the presence of glomerular mesangial IgA deposits, accompanied by a wide spectrum of histopathological lesions [10]. Although the pathogenesis of IgAN remains incompletely elucidated, the current prevailing theory suggests that its development follows a classic “four-hit hypothesis” [11]. his process begins with the circulation of galactose-deficient immunoglobulin A1 (Gd-IgA1) [12], which is recognized by specific autoantibodies, leading to the formation of immune complexes. These complexes subsequently deposit in the glomerular mesangial area, where they trigger robust mesangial inflammation and crescentic responses through the activation of complement pathways [13]. In the present pediatric case, this diffuse mesangial proliferation was profoundly intense at the initial presentation. Light microscopy revealed small cellular crescents in half of the glomeruli, signifying a severe and active intra-glomerular inflammatory response at that time point. Traditionally, the standard regimen for IgAN involves intensive cyclophosphamide combined with mycophenolate mofetil (MMF) or systemic corticosteroids [14]. Unlike traditional therapies that primarily address the downstream consequences of mesangial IgA accumulation, Nefecon is specifically designed to target the upstream immune processes underlying IgA nephropathy pathophysiology. By delivering budesonide directly to the Peyer’s patches in the distal ileum, Nefecon selectively modulates the gut-associated lymphoid tissue (GALT), the primary site of excess Gd-IgA1 production [15]. Nefecon was shown to significantly reduce serum levels of Gd-IgA1 after 9 months of treatment, as well as IgA-IgG immune complexes [16]. This localized, disease-modifying approach offers a significant advantage in pediatric populations. Budesonide’s high receptor affinity combined with extensive first-pass metabolism in the liver ensures potent immunomodulation with low systemic exposure and a reduced risk of concentration-dependent adverse effects [17]. This profile is vital for preserving the growth, development, and metabolic health of pediatric patients, while circumventing the irreversible toxicities associated with systemic cytotoxic agents, such as cyclophosphamide-induced gonadotoxicity. The clinical efficacy of this strategy is further corroborated by the full 2-year results of the Phase III NefIgArd trial, which demonstrated that 9 months of Nefecon treatment provided a statistically significant and clinically relevant preservation of kidney function—showing a 5.1 mL/min/1.73 m² eGFR benefit over 2 years—and a durable reduction in proteinuria compared to optimized RAS inhibition alone [16, 18]. Anti-GBM disease is an autoimmune disorder primarily characterized by rapidly progressive glomerulonephritis, pulmonary hemorrhage, and the presence of circulating autoantibodies [19]. These anti-GBM antibodies are directed against specific epitopes of an autoantigen within type IV collagen, the principal structural component of renal and pulmonary basement membranes. This antigen has been specifically identified as the α3(IV)NC1 [20, 21]. Peptides within α3(IV)NC1 serve as B-cell epitopes, which are recognized by pathogenic autoantibodies that drive the progression of rapidly progressive glomerulonephritis [22–24]. However, reports of the concurrent or sequential occurrence of anti-GBM disease and immune-complex-mediated glomerulonephritis remain scarce. It has been documented that anti-GBM disease can be secondary to various forms of glomerulonephritis [3], including MN, IgAN, membranoproliferative glomerulonephritis (MPGN), focal segmental glomerulosclerosis (FSGS), and lupus nephritis. Among these, the association with MN is relatively common, whereas its occurrence with IgAN is exceptionally rare. The causal link between these two entities remains elusive, though they may be pathophysiologically intertwined through several mechanisms. One hypothesis posits that the deposition of IgA immune complexes within the glomerular mesangium triggers the proliferation and infiltration of monocytes and macrophages [25, 26]. This process leads to the massive release of various inflammatory mediators, such as IL-1β, TNF, IL-2R, oxygen free radicals, and eicosanoids [27, 28]. These mediators, through paracrine effects, induce a complex immune and inflammatory cascade, ultimately resulting in conformational changes within the GBM. Such changes expose the previously cryptic NC1 of the type IV collagen α3 chain to the systemic circulation [21]. This re-exposure of antigens disrupts established immune homeostasis and stimulates the production of anti-GBM antibodies exceeding the clinical threshold [3]. Another plausible hypothesis focuses on the defective galactosylation of IgA1 in IgAN. The autoantibodies targeting Gd-IgA1 are predominantly of the IgG2 subclass [29, 30]. Given that IgA1 with abnormal polysaccharide chains and anti-GBM IgG2 have been detected along the GBM in patients with concurrent anti-GBM disease and IgAN, it is speculated that abnormal IgA1 deposition on the GBM may trigger the formation of neoantigens, thereby inducing anti-GBM antibody production [3]. In addition, the patient had a respiratory tract infection during the clinical course. Exogenous pathogenic antigens may induce cross-immune reactions with GBM antigens via molecular mimicry, subsequently triggering the formation of anti-GBM antibodies. In the present case, the patient was confirmed to be anti-GBM antibody-negative at the time of initial IgAN diagnosis, suggesting that IgAN preceded the development of anti-GBM nephritis. While the temporal sequence in this case—where IgAN preceded the seroconversion of anti-GBM antibodies—is striking, it remains plausible that their co-occurrence is coincidental rather than causative. However, due to the current lack of specific biomarkers to distinguish primary from secondary anti-GBM disease, it remains challenging to definitively prove whether anti-GBM disease in this context represents an incidental complication or a true secondary manifestation of IgAN. Further research is warranted to elucidate this relationship. In summary, we report a pediatric case of anti-GBM disease diagnosed during the clinical course of IgAN. The patient developed anti-GBM nephritis approximately four months after the initial diagnosis of IgAN, with a significant seroconversion of anti-GBM antibodies from negative to strongly positive. Evidence suggests that patients with anti-GBM disease and concomitant glomerular mesangial IgA deposition may exhibit less severe renal damage, more favorable renal outcomes, and a better response to therapy compared to those with typical anti-GBM disease. Early detection and prompt intervention are essential for patients presenting with anti-GBM disease and mesangial IgA deposits to achieve an optimal renal prognosis.